« Back to Team
Dirk joined Mersana in 2018, bringing 25 years of drug development experience within the biotech and pharmaceutical industries, including significant experience in the development and approval of ADCs. Prior to joining Mersana, Dirk served as Vice President, Head of Development, for Boston Biomedical, where he built a robust clinical development team and oversaw the clinical development of several early stage compounds, including the Phase 3 program of napabucasin, a cancer stem cell inhibitor. Prior to that, Dirk spent six years at Takeda Oncology (previously known as Millennium Pharmaceuticals) as Executive Medical Director. During his tenure at Takeda Oncology, Dirk served as the global clinical lead for ADCETRIS® (brentuximab vedotin), an ADC indicated for the treatment of Hodgkin lymphoma and certain CD30 positive T-cell lymphomas. In that role, he led the regulatory approval of ADCETRIS in Europe, and the design and implementation of the subsequent registration-enabling studies for the compound. Prior to Takeda, Dirk held roles of increasing leadership and responsibility in global clinical drug development at Genzyme, Roche, and Bristol-Myers Squibb.
Dr. Huebner received his Medical Doctor degree from the Free University in Berlin, Germany and pursued a medical residency in the Department of Urology, at University Hospital Eppendorf, in Hamburg.
If time allows between work and other family commitments, Dirk likes to go out for a run or a bicycle ride. This keeps his body and mind in sync!